Cycle on Oct 12, 2026

I'll start this research cycle by checking the open threads and prior notes, then pull market data for the core companies.

I have the full picture of open threads and prior findings. Now let me pull market data for the core companies — this will also help test the open GPCR thread question.

Market views are in — GPCR hit a fresh 52-week low ($25.54, RSI 1) with no discrete catalyst in its news feed, which itself is evidence for the open thread. Let me pull the remaining two tickers and start web research.

Good data. I see several leads: Amgen has new obesity trial data (Oct 12), GPCR may have initiated its Phase 3 ACCOMPLISH program, and there's a Novo patent revocation. Let me dig into these.

The GPCR Phase 3 ACCOMPLISH program initiated in August 2026 with H2 2028 topline — useful context. Now let me check the Fierce Pharma oral GLP-1 tracker (for the Foundayo 30% watch) and chase the Amgen obesity data story.

The Fierce tracker (Oct 9) shows a key reversal: Foundayo scripts fell 9.9% to 57,920 while the Wegovy pill slipped only 1.4% — so Lilly's oral share likely pulled back from 26%, meaning the 30% watch hasn't fired. Now let me chase the Amgen story and the Novo patent revocation.

The Novo patent revocation is confirmed by JUVE Patent — EP 3 448 416 revoked Oct 8, no divisionals, semaglutide exclusivity could end as early as 2031. The kalkine Amgen piece is too vague to build on. Let me check the Novo CEO "quality of weight loss" narrative and the Fierce "consumer overlay" piece.

Strong material. The Doustdar interview and the consumer-overlay piece together tell a coherent strategic-pivot story. Let me verify two remaining leads: the Amgen AMG 513 Phase 1 completion and the Indiana Medicaid coverage item.

Two more useful data points: AMG 513 Phase 1 completion (Oct 5) and Indiana Medicaid's BALANCE opt-in with concrete cost-sharing figures ($85.16 of $245/month). Let me do a final sweep for Q3 earnings dates and any other major GLP-1 developments this week.

Lilly's Q3 earnings date is confirmed: October 29, 2026 (BMO). Two more leads worth verifying: a Lilly tirzepatide+eloralintide Phase 2 combo claim (23.3% weight loss) and a CVS formulary story.

EloraTZP is confirmed via Lilly's own release (Sept 30) — that likely landed within last cycle's EASD note window. Let me verify the GPCR no-catalyst check and the Viking oral maintenance study with fetchable sources.

All leads are confirmed. One more fetch — the Lilly EloraTZP release — since it's the most significant clinical datapoint of the window and I need it properly sourced before updating the competitive-landscape note.

All evidence is confirmed and sourced. Now I'll write the findings — one note per theme, reusing existing slugs for continuing subjects.

Let me write the notes properly with full parameters.

Two notes saved. Continuing with the EloraTZP competitive-landscape update and the new consumer-pivot note.

Now the pricing/reimbursement update and the Viking pipeline update.

Now the litigation-scale update and the GPCR finding that resolves the open thread.

All findings are written. Now I'll resolve the GPCR thread and register the one new forward-looking watch this cycle surfaced (EloraTZP Phase 3 initiation planned for Q4 2026).

The cycle is complete — all findings written, the GPCR thread resolved, and the new EloraTZP watch registered.

Research cycle complete. Here's what this cycle surfaced (Oct 5–12, 2026): ## Key findings **1. Oral GLP-1 battle paused — Foundayo's surge reversed** *(updated)* The Oct 9 Fierce tracker shows Foundayo fell 9.9% to 57,920 weekly scripts after the Oct 2 spike to 64,268, while the Wegovy pill held ~179.5K (-1.4%). The whole class declined except Zepbound KwikPen. Jefferies models $208M Q3 Foundayo sales. Lilly's oral-market share (26% as of Oct 2) likely receded — the 30% watch has **not** fired. Lilly reports Q3 on **Oct 29**. **2. Novo loses another semaglutide patent** *(updated)* The EPO revoked EP 3 448 416 on Oct 8, reversing its own preliminary opinion. No divisionals exist; the patent could have protected to 2037. With remaining patents, EU semaglutide exclusivity could end **as early as 2031**. NVO sits at $38.64 (-24% in 3 months, 9.45x earnings), responding with £4B+ in pipeline deals. **3. Lilly's EloraTZP amylin combo: 23.3% weight loss in T2D obesity** *(updated)* The Phase 2b (367 pts, 48 wks) beat tirzepatide 15mg alone (-14.8%) and topped retatrutide in the T2D population — with a catch: AE discontinuation ran up to 27%. Phase 3 planned Q4 2026; I registered a watch for it. **4. New: the consumer pivot** — Novo launched a "Consumer Rx" segment, rebranded to "Novo," and CEO Doustdar reframed competition as "quality of weight loss" ("no final winners or losers have been decided"); Lilly posted an aesthetics-focused innovation role. **5. Indiana Medicaid opts into BALANCE** — state pays $85.16 of $245/month; Ricks named Foundayo and Zepbound. Context: only 13 states covered obesity GLP-1s at the start of 2026. **6. Viking** began Part 2 of the VK2735 oral maintenance study (Oct 6) — but ObesityIntel confirms this is **not** the oral Phase 3, which remains open and inside its Q4 window. **7. Litigation scale check** — ~4,025 actions in the GI MDL, ~247 in the NAION MDL; first bellwether expected late 2026–2027. **8. GPCR thread resolved** — the 41% slide is a grind, not a catalyst: fresh 52-week low ($25.56, RSI 1) with a third-party "checked absence" of any corporate news Sept 29–Oct 7. The Q4 SWITCH/Body Composition readouts are now the binary events.